Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130713 | 0.91 | ESR1 (0.59) | CYP3A4USP2ESR1AKR1C4AKR1C3 | |
| Methylorsellinic Acid, Ethyl Ester SCHEMBL4117805 | 0.88 | CYP3A4 (0.67) | CYP3A4USP2TDP1SMN1; SMN2NR1H2 | |
| Methylorsellinic Acid, Ethyl Ester SCHEMBL29814224 | 0.88 | CYP3A4 (0.67) | CYP3A4USP2TDP1SMN1; SMN2NR1H2 | |
| SCHEMBL10722726 | 0.80 | CYP3A4 (0.81) | CYP3A4USP2TDP1SMN1; SMN2NR1H2 | |
| Atraric Acid SCHEMBL113732 | 0.78 | CYP3A4 (0.59) | CYP3A4USP2TDP1SMN1; SMN2HPGD | |
| Atraric Acid SCHEMBL29357076 | 0.78 | CYP3A4 (0.59) | CYP3A4USP2TDP1SMN1; SMN2HPGD | |
| SCHEMBL11321147 | 0.76 | CYP3A4 (0.69) | CYP3A4USP2TDP1SMN1; SMN2NR1H2 | |
| SCHEMBL31643773 | 0.76 | TDP1 (0.51) | CYP3A4USP2TDP1SMN1; SMN2HPGD | |
| SCHEMBL784911 | 0.75 | MAPT (0.49) | CYP3A4TDP1SMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL16242748 | 0.74 | CYP3A4 (0.52) | CYP3A4USP2TDP1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481519-B2 | Isolation of atraric acid, synthesis of atraric acid derivatives, and use of atraric acid and the derivatives thereof for the treatment of benign prostatic hyperplasia, prostate carcinoma and spinobulbar muscular atrophy | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2013-07-09 | — | — | US | disclosed |
| EP-1850857-B1 | ISOLATION OF ATRARIC ACID, SYNTHESIS OF ATRARIC ACID DERIVATIVES, AND USE OF ATRARIC ACID AND THE DERIVATIVES THEREOF FOR THE TREATMENT OF PROSTATE CARCINOMA. | LOHMANN THERAPIE SYST LTS (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-20090143466-A1 | Isolation of Atraric Acid, Synthesis of Atraric Acid Derivatives, and Use of Atraric Acid and the Derivatives Thereof for the Treatment of Benign Prostatic Hyperplasia, Prostate Carcinoma and Spinobulbar Muscular Atrophy | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143466-A1 | Isolation of Atraric Acid, Synthesis of Atraric Acid Derivatives, and Use of Atraric Acid and the Derivatives Thereof for the Treatment of Benign Prostatic Hyperplasia, Prostate Carcinoma and Spinobulbar Muscular Atrophy | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143466-A1 | Isolation of Atraric Acid, Synthesis of Atraric Acid Derivatives, and Use of Atraric Acid and the Derivatives Thereof for the Treatment of Benign Prostatic Hyperplasia, Prostate Carcinoma and Spinobulbar Muscular Atrophy | RARB, RARA, AR | CYP3A4 3211/4885USP2 2706/4885TDP1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.